HRP20150518T1 - Antibakterijski spojevi - Google Patents
Antibakterijski spojevi Download PDFInfo
- Publication number
- HRP20150518T1 HRP20150518T1 HRP20150518TT HRP20150518T HRP20150518T1 HR P20150518 T1 HRP20150518 T1 HR P20150518T1 HR P20150518T T HRP20150518T T HR P20150518TT HR P20150518 T HRP20150518 T HR P20150518T HR P20150518 T1 HRP20150518 T1 HR P20150518T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- bibenzo
- use according
- imidazole
- subjects
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 16
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- UHQFBTAJFNVZIV-UHFFFAOYSA-N 2-pyridin-4-yl-6-(2-pyridin-4-yl-3h-benzimidazol-5-yl)-1h-benzimidazole Chemical group C1=NC=CC(C=2NC3=CC=C(C=C3N=2)C=2C=C3N=C(NC3=CC=2)C=2C=CN=CC=2)=C1 UHQFBTAJFNVZIV-UHFFFAOYSA-N 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- IQEWIIWKWPCQIU-UHFFFAOYSA-N 2-(4-methoxyphenyl)-6-(2-phenyl-3h-benzimidazol-5-yl)-1h-benzimidazole Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C=C4N=C(NC4=CC=3)C=3C=CC=CC=3)C=C2N1 IQEWIIWKWPCQIU-UHFFFAOYSA-N 0.000 claims 1
- QSHOHAZUJFNTGA-UHFFFAOYSA-N 2-(4-methoxyphenyl)-6-[2-(4-methoxyphenyl)-3h-benzimidazol-5-yl]-1h-benzimidazole Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC(C=3C=C4N=C(NC4=CC=3)C=3C=CC(OC)=CC=3)=CC=C2N1 QSHOHAZUJFNTGA-UHFFFAOYSA-N 0.000 claims 1
- QROWVLFOWUYBIG-UHFFFAOYSA-N 3-[6-[2-(3-aminophenyl)-3h-benzimidazol-5-yl]-1h-benzimidazol-2-yl]aniline Chemical compound NC1=CC=CC(C=2NC3=CC(=CC=C3N=2)C=2C=C3NC(=NC3=CC=2)C=2C=C(N)C=CC=2)=C1 QROWVLFOWUYBIG-UHFFFAOYSA-N 0.000 claims 1
- QJPVRWMVJMSSSJ-UHFFFAOYSA-N 4-[6-[2-(4-aminophenyl)-1-methylbenzimidazol-5-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C=1C=C2N(C)C(C=3C=CC(N)=CC=3)=NC2=CC=1C(C=C1N=2)=CC=C1NC=2C1=CC=C(N)C=C1 QJPVRWMVJMSSSJ-UHFFFAOYSA-N 0.000 claims 1
- DGMYEDVRVIEGBG-UHFFFAOYSA-N 4-[6-[2-(4-aminophenyl)-3-methylbenzimidazol-5-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C1=C2N(C)C(C=3C=CC(N)=CC=3)=NC2=CC=C1C(C=C1N=2)=CC=C1NC=2C1=CC=C(N)C=C1 DGMYEDVRVIEGBG-UHFFFAOYSA-N 0.000 claims 1
- MTXGSGLDYXIXFF-UHFFFAOYSA-N 4-[6-[2-(4-aminophenyl)-3h-benzimidazol-5-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=C(C=3C=C4NC(=NC4=CC=3)C=3C=CC(N)=CC=3)C=C2N1 MTXGSGLDYXIXFF-UHFFFAOYSA-N 0.000 claims 1
- UHUVPVREKSWRCU-UHFFFAOYSA-N 5-[6-[2-(6-aminopyridin-3-yl)-3h-benzimidazol-5-yl]-1h-benzimidazol-2-yl]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=NC2=CC(C=3C=C4N=C(NC4=CC=3)C=3C=NC(N)=CC=3)=CC=C2N1 UHUVPVREKSWRCU-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000037384 Clostridium Infections Diseases 0.000 claims 1
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- LUIYJLIHLJLIPT-UHFFFAOYSA-N chembl34682 Chemical compound C1=CC(O)=CC=C1C1=NC2=CC=C(C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C=C2N1 LUIYJLIHLJLIPT-UHFFFAOYSA-N 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000005399 mechanical ventilation Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- CAFCKYMPWSAZTC-UHFFFAOYSA-N n-methyl-4-[6-[2-[4-(methylamino)phenyl]-3h-benzimidazol-5-yl]-1h-benzimidazol-2-yl]aniline Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC(C=3C=C4N=C(NC4=CC=3)C=3C=CC(NC)=CC=3)=CC=C2N1 CAFCKYMPWSAZTC-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (14)
1. Spoj s formulom (I):
[image]
pri čemu:
L1 je izravna veza;
R1 i R2 su svaki neovisno odabrani od H i proizvoljno supstituiranog C1-6 alkila, arila, heteroarila, karbociklila i heterociklila, proizvoljna supstitucija je s jednim ili više supstituenata odabranih od halo, CN, NO2, R6, OR6, N(R6)2, COR6, CO2R6, SO2R6, NR7COR6, NR7CO2R6, NR7SO2R6, NR7CONR6R7, CONR6R7 i SO2NR6R7, uz uvjet da barem jedan od R1 i R2 je ciklički;
svaki R5 je neovisno odabran od H, halo, C1-6 alkil, OR7, N(R7)2, CN i NO2;
X1 i X2 su svaki neovisno odabrani od N i CR3;
X3 je odabran od NR4, O i S;
X4 je NH; i
R3 je odabran od H, halo i C1-6 alkil; R4 je odabran od H i C1-6 alkila; R6 je odabran od H, C1-C6 alkila, C2-C6 alkenila, C2-C6 alkinila, C4-C7 karbociklila, C4-C7 heterociklila i 5- ili 6- članog arila ili heteroarila, od kojih svaki može biti po izboru supstituiran s jednim ili više halo atoma; i R7 je odabran od vodika i C1-C4 alkila, od kojih svaki je po izboru supstituiran s jednim ili više halo atoma;
ili njegov farmaceutski prihvatljiv N-oksid, sol, hidrat ili solvat naznačen time da je za uporabu u postupku liječenja: infekcije s Clostridium difficile ili bolesti povezane s Clostridium difficile (CDAD) koja je odabrana od: (a) kolitisa; (b) pseudomembranskog kolitisa; te (c) proljeva uzrokovanog s Clostridium difficile.
2. Spoj za uporabu prema zahtjevu 1 naznačen time da X1 i/ili X2 je N.
3. Spoj za uporabu prema zahtjevu 1 ili zahtjevu 2 naznačen time da X3 je NR4.
4. Spoj za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da R1 i R2 su: (a) svaki neovisno odabrani od H i arila; (b) svaki neovisno odabran od H i arila proizvoljno supstituiranog s OR6 i N(R6)2; (c) svaki ciklički; (d) isti; (e) različiti; ili (f) heterociklil ili heteroaril.
5. Spoj za uporabu prema bilo kojem zahtjevu od 1 do 4 naznačen time da R1 i/ili R2 je (su): (a) heterociklil supstituiran s jednim ili više supstituenata odabranih od halo, CN, NO2, R6, OR6, N(R6)2, COR6, CO2R6, SO2R6, NR7COR6, NR7CO2R6, NR7SO2R6, NR7CONR6R7, CONR6R7 i SO2NR6R7; ili (b) heteroaril supstituiran s jednim ili više supstituenata odabranih od halo, CN, NO2, R6, OR6, N(R6)2, COR6, CO2R6, SO2R6, NR7COR6, NR7CO2R6, NR7SO2R6, NR7CONR6R7, CONR6R7 i SO2NR6R7.
6. Spoj za uporabu prema zahtjevu 5 naznačen time da R1 i/ili R2 je (su) piridil.
7. Spoj za uporabu prema zahtjevu 6 naznačen time da piridil je supstituiran s jednim ili više supstituenata odabranih od halo, CN, NO2, R6, OR6, N(R6)2, COR6, CO2R6, SO2R6, NR7COR6, NR7CO2R6, NR7SO2R6, NR7CONR6R7, CONR6R7 i SO2NR6R7.
8. Spoj za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da R6 je odabran od H i C1-C6alkila i/ili svaki R5 je H.
9. Spoj za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da L1 je izravna veza između 5 i/ili 6 položaja na svakom ciklu.
10. Spoj za uporabu prema zahtjevu 1 naznačen time da je 2,2'-di(piridin-4-il)-1H,1'H-5,5'-bibenzo[d]imidazol, ili njegov farmaceutski prihvatljiv N-oksid, sol, hidrat ili solvat.
11. Spoj za uporabu prema zahtjevu 1 naznačen time da je odabran od:
4,4'-(1H,3'H-5,5'-bibenzo[d]imidazol-2,2'-diil)dianilina;
3,3'-(1H,1'H-5,5'-bibenzo[d]imidazol-2,2'-diil)dianilina;
4,4'-(1H,1'H-5,5'-bibenzo[d]imidazol-2,2'-diil)difenola;
4,4'-(3'-metil-1H,3'H-5,5'-bibenzo[d]imidazol-2,2'-diil)dianilina;
4,4'-(1-metil-1H,1'H-5,5'-bibenzo[d]imidazol-2,2'-diil)dianilina;
4,4'-(1H,1'H-5,5'-bibenzo[d]imidazol-2,2'-diil)bis(N-metilanilin);
2,2'-bis(4-metoksifenil)-1H,1'H-5,5'-bibenzo[d]imidazola;
4-((1H,1'H-5,5'-bibenzo[d]imidazol-2-il)anilina;
4-((2'-fenil-1 H,1'H-5,5'-bibenzo[d]imidazol-2-il)anilina;
2'-(4-metoksifenil)-2-fenil-1H,3'H-5,5'-bibenzo[d]imidazola;
5,5'-(1H,1'H-5,5'-bibenzo[d]imidazol-2,2'-diil)dipiridin-2-amina;
2,2'-di(piridin-4-il)-1H,1'H-5,5'-bibenzo[d]imidazola; te
farmaceutski prihvatljivi N-oksidi, soli, hidrati ili solvati bilo kojeg od gore navedenih spojeva.
12. Spoj za uporabu prema zahtjevu 1 naznačen time da:
R1 i R2 su svaki neovisno odabrani od H i proizvoljno supstituiranog arila, heteroarila, a proizvoljna supstitucija je s jednim ili više supstituenata odabranih od OR6, N(R6)2, uz uvjet da najmanje jedan od R1 i R2 je ciklički;
R5 je H;
X1 i X2 su N;
X3 je NR4, pri čemu R4 je H ili metil; i
X4 je NH.
13. Spoj za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da navedeni postupak liječenja CDAD pošteđuje normalnu crijevnu floru.
14. Spoj za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da navedeni postupak liječenja CDAD je za podskupinu pacijenata odabranu od: (a) subjekata koji su podvrgavani, ili se podvrgavaju tretmanu s inhibitorima protonske pumpe; (b) subjekata koji su podvrgavani, ili se podvrgavaju tretmanu s antagonistima H2 receptora; (c) subjekata koji su podvrgavani, ili se podvrgavaju tretmanu s diureticima; (d) hospitaliziranih subjekata; (e) subjekata s unutarnjim cjevčicama za hranjenje; (f) subjekata koja se podvrgavaju mehaničkoj ventilaciji; (g) subjekata koji su podvrgavani, ili se podvrgavaju tretmanu s probioticima; te (g) subjekata koji su podvrgavani, ili se podvrgavaju tretmanu, s vankomicinom i/ili metronidazolom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0821913.1A GB0821913D0 (en) | 2008-12-02 | 2008-12-02 | Antibacterial compounds |
PCT/GB2009/002792 WO2010063996A2 (en) | 2008-12-02 | 2009-12-01 | Antibacterial compounds |
EP09795514.0A EP2373631B1 (en) | 2008-12-02 | 2009-12-01 | Antibacterial compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150518T1 true HRP20150518T1 (hr) | 2015-07-17 |
Family
ID=40262471
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150518TT HRP20150518T1 (hr) | 2008-12-02 | 2015-05-14 | Antibakterijski spojevi |
HRP20160597TT HRP20160597T1 (hr) | 2008-12-02 | 2016-06-03 | Antibakterijske farmaceutske kompozicije |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160597TT HRP20160597T1 (hr) | 2008-12-02 | 2016-06-03 | Antibakterijske farmaceutske kompozicije |
Country Status (28)
Country | Link |
---|---|
US (3) | US8975416B2 (hr) |
EP (3) | EP2907813B1 (hr) |
JP (3) | JP5665756B2 (hr) |
KR (1) | KR101643435B1 (hr) |
CN (1) | CN102227411B (hr) |
AU (1) | AU2009323854B2 (hr) |
BR (2) | BRPI0922220B8 (hr) |
CA (1) | CA2744962C (hr) |
CY (2) | CY1116383T1 (hr) |
DK (2) | DK2907813T3 (hr) |
ES (2) | ES2537059T3 (hr) |
GB (1) | GB0821913D0 (hr) |
HK (2) | HK1162169A1 (hr) |
HR (2) | HRP20150518T1 (hr) |
HU (1) | HUE029151T2 (hr) |
IL (1) | IL213325A (hr) |
LT (1) | LT2907813T (hr) |
MX (1) | MX2011005837A (hr) |
NZ (1) | NZ593111A (hr) |
PL (2) | PL2907813T3 (hr) |
PT (2) | PT2907813T (hr) |
RS (1) | RS54904B1 (hr) |
RU (1) | RU2525915C2 (hr) |
SG (1) | SG171939A1 (hr) |
SI (2) | SI2907813T1 (hr) |
SM (2) | SMT201500117B (hr) |
WO (1) | WO2010063996A2 (hr) |
ZA (1) | ZA201103751B (hr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
AU2011260097B2 (en) | 2010-06-01 | 2015-01-22 | Summit (Oxford) Limited | Compounds for the treatment of clostridium difficile associated disease |
GB2480816A (en) * | 2010-06-01 | 2011-12-07 | Summit Corp Plc | Compounds for the treatment of Clostridium difficile associated diseases |
GB2480814A (en) * | 2010-06-01 | 2011-12-07 | Summit Corp Plc | Compounds for the treatment of clostridium difficile-associated disease |
GB2480813A (en) * | 2010-06-01 | 2011-12-07 | Summit Corp Plc | Compounds for the treatment of clostridium difficile-associated disease |
WO2011151620A1 (en) * | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
WO2011151619A1 (en) * | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
US9079935B2 (en) | 2012-08-13 | 2015-07-14 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Reducing risk of contracting Clostridium-difficile associated disease |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
US10973861B2 (en) | 2013-02-04 | 2021-04-13 | Seres Therapeutics, Inc. | Compositions and methods |
EP3584308A3 (en) | 2013-02-04 | 2020-03-04 | Seres Therapeutics, Inc. | Compositions and methods |
JP2016519664A (ja) | 2013-03-15 | 2016-07-07 | セレス セラピューティクス インコーポレイテッド | ネットワークを基にした微生物組成物及び方法 |
MX367109B (es) | 2013-11-25 | 2019-08-05 | Seres Therapeutics Inc | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. |
EP3082431A4 (en) | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
JP6526956B2 (ja) * | 2013-12-19 | 2019-06-05 | 花王株式会社 | 固形状組成物 |
US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
US20180000793A1 (en) * | 2015-02-06 | 2018-01-04 | Ernesto Abel-Santos | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis |
WO2019036510A1 (en) | 2017-08-14 | 2019-02-21 | Seres Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASE |
US11512068B2 (en) | 2017-10-05 | 2022-11-29 | Sandoz Ag | Process for the preparation of crystalline ridinilazole using acid addition salts |
US20220289705A1 (en) | 2019-07-17 | 2022-09-15 | Summit (Oxford) Limited | Process for the preparation of ridinilazole and crystalline forms thereof |
EP4069691A1 (en) | 2019-12-06 | 2022-10-12 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
US20210324009A1 (en) * | 2020-04-17 | 2021-10-21 | The University Of Hong Kong | Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections |
GB202100471D0 (en) | 2021-01-14 | 2021-03-03 | Summit Oxford Ltd | Preparation of antibacterial compounds |
GB202100470D0 (en) * | 2021-01-14 | 2021-03-03 | Summit Oxford Ltd | Solid tablet dosage for of ridinilazole |
KR20240011728A (ko) * | 2021-05-24 | 2024-01-26 | 에임맥스 테라퓨틱스, 인코포레이티드 | 세균 감염의 치료 또는 예방을 위한 프리스티나마이신 ia 및 플로프리스틴 조합 |
CA3221259A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
IL309232A (en) | 2021-06-14 | 2024-02-01 | Scorpion Therapeutics Inc | History of urea which can be used to treat cancer |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3661849A (en) * | 1965-10-06 | 1972-05-09 | Ashland Oil Inc | Heterocyclic polyimides prepared from heterocyclic diamines |
US3503929A (en) * | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
DE1670684A1 (de) | 1966-04-01 | 1970-12-03 | Hoechst Ag | Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten |
US4087409A (en) * | 1966-11-07 | 1978-05-02 | Monsanto Company | Ordered heterocyclic copolymers |
JPS50140445A (hr) * | 1974-04-30 | 1975-11-11 | ||
JPS50154250A (hr) * | 1974-05-31 | 1975-12-12 | ||
JPH03500661A (ja) * | 1988-06-09 | 1991-02-14 | ザ・ダウ・ケミカル・カンパニー | ベンゾキサゾール,ベンゾチアゾールまたはベンズイミダゾールの少なくとも1つの結合によって架橋したビスシクロブタレンのモノマー,オリゴマー及びポリマー |
US5089592A (en) | 1988-06-09 | 1992-02-18 | The Dow Chemical Company | Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage |
GB9108279D0 (en) * | 1991-04-18 | 1991-06-05 | Ucb Sa | A method of preparing 1h-benzimidazoles |
US5317078A (en) * | 1991-10-30 | 1994-05-31 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Polybenzimidazole via aromatic nucleophilic displacement |
CN1164227A (zh) * | 1994-11-17 | 1997-11-05 | 弗·哈夫曼-拉罗切有限公司 | 联苯并咪唑衍生物 |
AU3696495A (en) * | 1994-11-17 | 1996-06-17 | F. Hoffmann-La Roche Ag | Antibacterial dibenzimidazole derivatives |
US5770617A (en) | 1996-03-20 | 1998-06-23 | Rutgers, The State University Of New Jersey | Terbenzimidazoles useful as antifungal agents |
JPH11158156A (ja) | 1997-12-03 | 1999-06-15 | Earth Chem Corp Ltd | 新規な1−(4−アルキルオキシフェニル)イミダゾール化合物 |
JPH11158158A (ja) * | 1997-12-03 | 1999-06-15 | Snow Brand Milk Prod Co Ltd | 新規ベンゾイミダゾール誘導体 |
US6358930B1 (en) | 1998-05-28 | 2002-03-19 | Synsorb Biotech Inc. | Treatment of C. difficile toxin B associated conditions |
JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
GB9908828D0 (en) | 1999-04-16 | 1999-06-16 | Univ Reading The | Compounds |
JP4307071B2 (ja) | 2000-11-27 | 2009-08-05 | チバ ホールディング インコーポレーテッド | Uv吸収剤としての置換5−アリール及び5−ヘテロアリール−2−(2−ヒドロキシフェニル)−2h−ベンゾトリアゾール誘導体 |
CA2433197C (en) | 2000-12-15 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
FR2819180B1 (fr) * | 2001-01-11 | 2003-02-21 | Oreal | Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe |
AU2002228317A1 (en) * | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Benz-1,3-azole derivatives and their uses as heparanase inhibitors |
WO2004001058A2 (en) | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
RU2333208C2 (ru) | 2002-06-13 | 2008-09-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций |
WO2004035522A1 (ja) * | 2002-08-30 | 2004-04-29 | Bf Research Institute, Inc. | プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤 |
EP1558341A4 (en) | 2002-11-01 | 2010-09-08 | Paratek Pharm Innc | TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE |
WO2006076009A2 (en) | 2004-04-23 | 2006-07-20 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
KR100629060B1 (ko) * | 2004-08-11 | 2006-09-26 | 주식회사 엘지화학 | 새로운 벤즈이미다졸계 화합물 |
AU2005304784B2 (en) | 2004-11-04 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
US20090069384A1 (en) | 2005-01-19 | 2009-03-12 | Biolipox Ab | Thienopyrroles useful in the treatment of inflammation |
EP1945209B1 (en) | 2005-08-12 | 2018-05-30 | United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command | Broad spectrum antibacterial compounds |
CN101321744A (zh) | 2005-11-07 | 2008-12-10 | 沃泰克斯药物股份有限公司 | 作为回旋酶抑制剂的苯并咪唑衍生物 |
KR100744827B1 (ko) * | 2006-04-05 | 2007-08-01 | 한국화학연구원 | 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법 |
GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
AU2007291190A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
PE20080888A1 (es) * | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
WO2008073451A2 (en) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Benzoimidazole derivatives as sirtuin (sir) modulating compounds |
JP2010513263A (ja) | 2006-12-15 | 2010-04-30 | ファイザー・プロダクツ・インク | ベンズイミダゾール誘導体 |
EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
KR101022649B1 (ko) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치 |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0821913D0 (en) * | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
SG10201400235PA (en) | 2009-02-27 | 2014-07-30 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
KR101219487B1 (ko) | 2009-03-03 | 2013-01-15 | 덕산하이메탈(주) | 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말 |
ES2548571T3 (es) | 2009-04-02 | 2015-10-19 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Derivados de imidazo[2,1-b][1,3,4]tiadiazol |
CA2763624A1 (en) | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Pyrimidine inhibitors of kinase activity |
CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
ES2632220T3 (es) | 2009-06-15 | 2017-09-11 | Rigel Pharmaceuticals, Inc. | Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK) |
CA2777565C (en) | 2009-10-13 | 2019-06-18 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses |
AU2011260097B2 (en) | 2010-06-01 | 2015-01-22 | Summit (Oxford) Limited | Compounds for the treatment of clostridium difficile associated disease |
-
2008
- 2008-12-02 GB GBGB0821913.1A patent/GB0821913D0/en not_active Ceased
-
2009
- 2009-12-01 ES ES09795514.0T patent/ES2537059T3/es active Active
- 2009-12-01 HU HUE14197877A patent/HUE029151T2/hu unknown
- 2009-12-01 EP EP14197877.5A patent/EP2907813B1/en active Active
- 2009-12-01 SG SG2011040458A patent/SG171939A1/en unknown
- 2009-12-01 PT PT141978775T patent/PT2907813T/pt unknown
- 2009-12-01 EP EP09795514.0A patent/EP2373631B1/en active Active
- 2009-12-01 JP JP2011538052A patent/JP5665756B2/ja active Active
- 2009-12-01 ES ES14197877.5T patent/ES2575908T3/es active Active
- 2009-12-01 EP EP16155561.0A patent/EP3095783A1/en not_active Withdrawn
- 2009-12-01 RS RS20160458A patent/RS54904B1/sr unknown
- 2009-12-01 DK DK14197877.5T patent/DK2907813T3/en active
- 2009-12-01 LT LTEP14197877.5T patent/LT2907813T/lt unknown
- 2009-12-01 MX MX2011005837A patent/MX2011005837A/es active IP Right Grant
- 2009-12-01 DK DK09795514.0T patent/DK2373631T3/en active
- 2009-12-01 CN CN200980148065.8A patent/CN102227411B/zh active Active
- 2009-12-01 BR BRPI0922220A patent/BRPI0922220B8/pt active IP Right Grant
- 2009-12-01 WO PCT/GB2009/002792 patent/WO2010063996A2/en active Application Filing
- 2009-12-01 PL PL14197877.5T patent/PL2907813T3/pl unknown
- 2009-12-01 PL PL09795514T patent/PL2373631T3/pl unknown
- 2009-12-01 SI SI200931456A patent/SI2907813T1/sl unknown
- 2009-12-01 KR KR1020117015273A patent/KR101643435B1/ko active IP Right Grant
- 2009-12-01 CA CA2744962A patent/CA2744962C/en active Active
- 2009-12-01 US US13/131,469 patent/US8975416B2/en active Active
- 2009-12-01 BR BR122020013025-3A patent/BR122020013025B1/pt active IP Right Grant
- 2009-12-01 RU RU2011127165/04A patent/RU2525915C2/ru active
- 2009-12-01 AU AU2009323854A patent/AU2009323854B2/en active Active
- 2009-12-01 PT PT97955140T patent/PT2373631E/pt unknown
- 2009-12-01 NZ NZ593111A patent/NZ593111A/xx unknown
- 2009-12-01 SI SI200931191T patent/SI2373631T1/sl unknown
-
2011
- 2011-05-23 ZA ZA2011/03751A patent/ZA201103751B/en unknown
- 2011-06-02 IL IL213325A patent/IL213325A/en active IP Right Grant
-
2012
- 2012-03-13 HK HK12102532.7A patent/HK1162169A1/xx unknown
-
2014
- 2014-12-09 JP JP2014249071A patent/JP2015078220A/ja active Pending
-
2015
- 2015-02-06 US US14/616,006 patent/US9314456B2/en active Active
- 2015-05-14 HR HRP20150518TT patent/HRP20150518T1/hr unknown
- 2015-05-15 CY CY20151100440T patent/CY1116383T1/el unknown
- 2015-05-18 SM SM201500117T patent/SMT201500117B/xx unknown
- 2015-09-17 HK HK15109126.1A patent/HK1208668A1/zh unknown
-
2016
- 2016-03-08 US US15/064,137 patent/US9763925B2/en active Active
- 2016-06-03 HR HRP20160597TT patent/HRP20160597T1/hr unknown
- 2016-06-24 CY CY20161100572T patent/CY1117934T1/el unknown
- 2016-08-03 SM SM201600259T patent/SMT201600259B/it unknown
- 2016-10-28 JP JP2016212160A patent/JP2017048217A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150518T1 (hr) | Antibakterijski spojevi | |
HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
EA201992120A1 (ru) | Новые ингибиторы | |
MX2010004293A (es) | Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet. | |
NO20073663L (no) | Tiazol-4-karboksamid-derivater som mGluR5 antagonister | |
PE20120403A1 (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
MX344669B (es) | Agente antiplaquetas novedoso. | |
PE20071171A1 (es) | Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropicos | |
EA201591240A1 (ru) | Композиции {3-[5-(4-хлорфенил)-1h-пирроло[2,3-b]пиридин-3-карбонил]-2,4-дифторфенил}амида пропан-1-сульфоновой кислоты и их применение | |
NO341631B1 (no) | Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger | |
NO20083582L (no) | Pyridin-2-karboksamide derivater | |
NO20070731L (no) | Heterocykliske forbindelser. | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
MXPA06002880A (es) | Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes. | |
PE20081692A1 (es) | Nuevo derivado de heterocicliden acetamida | |
NO20072806L (no) | Aryloksy-substituerte benzimidazolderivater | |
NO20092123L (no) | [F-18]-merket L-glutaminsyre, [F-18]-merket L-glutamin og derivater derav, anvendelse og fremgangsmate for fremstilling av disse | |
MY150062A (en) | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands | |
ATE457981T1 (de) | 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung | |
NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
NZ712352A (en) | Novel inhibitors of glutaminyl cyclase | |
NO20092341L (no) | Substituerte piperidiner inneholdende et heteroarylamid eller en heteroarylfenyl gruppe | |
MX369801B (es) | Compuesto heterociclico sustituido con halogeno. |